Showing 1 - 10 of 1,499
This paper examines the effect of foreign direct investment (FDI) on domestic innovation based on a data set covering the pharmaceutical industries across 29 provinces in the People's Republic of China (PRC) over the period 1998-2007. We show that there is a negative horizontal spillover effect...
Persistent link: https://www.econbiz.de/10011723712
Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our...
Persistent link: https://www.econbiz.de/10012604733
This paper aims to investigate the effect of knowledge characteristics on the total factor productivity of firms developing drugs in the pharmaceutical industry. We decompose knowledge into knowledge associated with the technological firm portfolio and knowledge related to R&D projects, which...
Persistent link: https://www.econbiz.de/10003989032
GLOBAL PRICE FIXING (2nd Edition) was released by Springer at the end of 2006. This note reproduces a 2002 review of the first edition of the book by Prof. Douglas Greer. It is reproduced with the permission of the publisher of the Review of Industrial Organization
Persistent link: https://www.econbiz.de/10012775648
Using a reduced form binary econometric model, we analyze the determinants of pharmaceutical companies entry decisions into new submarkets. Our sample includes data for pharmaceutical companies over the period 1987-1998 for seven countries. Estimation is done both at the aggregate level and at a...
Persistent link: https://www.econbiz.de/10012708979
This paper evaluates the effects of patent protection on pharmaceutical innovations for twenty-six countries that established pharmaceutical patent laws during 1978-2002. Controlling for country characteristics through matched sampling techniques to establish two proper comparison sets among...
Persistent link: https://www.econbiz.de/10012751759
Closing the loopholes of downstream application of the Capper-Volstead exemption in the food system and pay for delay in pharmaceuticals is an important advance in US and EU antitrust norms. First, pay-for-delay conduct has been harmful for pharmaceuticals customers. After ten years of...
Persistent link: https://www.econbiz.de/10012912713
New information technologies enable individuals in disparate locations to conduct cutting-edge research, to move that research into the development and testing of new medicines, to manufacture high-quality products, and to move those products to patients around the world. Conceptually, the world...
Persistent link: https://www.econbiz.de/10014041752
Persistent link: https://www.econbiz.de/10015062612
Persistent link: https://www.econbiz.de/10013170079